Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by bball67on Sep 13, 2022 8:50am
265 Views
Post# 34958935

New CEO

New CEOWell, they promised a new CEO and now we have one. I like it. The release says there was an extensive search. The Boston Group had to be involved and signed off. Her previous employer Zogenix (epilepsy) was sold for $1,9B in March 2022 with a likely 3 month transition situation, so the timing was right. Looks like she was a number two person there along with another EVP. She has broad experience. Looked at 4/15/21 Zogenix Proxy, there was institutional ownership of 5.6% to 9.6%, Blackrock, Morgan Stanley, RA Capital and Cadian Capital. Assume she was involved with these investors and that they would be candidates for Promis ownership. She has capital market experience and assume she was involved with their financings. It does appear that she is an outsider without connections to the existing management team. If Mike Gordon of FSG (Boston Group) supported and approved this hire, which I assume he did, then I think we have a winner. Let's watch and see what she does in the next few months. 
<< Previous
Bullboard Posts
Next >>